Sunitinib and other targeted therapies for renal cell carcinoma |
| |
| Authors: | Powles T Chowdhury S Jones R Mantle M Nathan P Bex A Lim L Hutson T |
| |
| Affiliation: | Department of Medical Oncology, St Bartholomew's Hospital London, Barts and the London NHS trust, Charterhouse Square, London, UK. thomas.polwes@bartsandthelondon.nhs.uk |
| |
| Abstract: | Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change. In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will describe the major areas of clinical research that will report over the next few years. |
| |
| Keywords: | renal cancer sunitinib mTOR VEGF |
| 本文献已被 PubMed 等数据库收录！ |
|
